drugset / Trial / NCT01369121

Tolerability Study of Xerecept® in Pediatric Patients

NCT01369121

Phase 1/2 Terminated 15 enrolled Celtic Pharma Development Services
NaSingle-groupOpen-labelTreatment

Summary

This study is being conducted to evaluate the safety and tolerability of Xerecept® in children with central nervous system tumors and to identify appropriate doses of Xerecept® to be used in subsequent pediatric clinical trials.

Timeline

Start
2010-06
Primary completion
2012-10
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Xerecept Unknown Subcutaneous